FindTrial
Sign In

CD7 CAR-T cells infusion

DRUG3 trials

Sponsors

PersonGen BioTherapeutics (Suzhou) Co., Ltd., Beijing GoBroad Hospital, Xuzhou Medical University

Conditions

Acute Lymphocytic LeukemiaAplastic AnaemiaCAR-TCD7 PositiveNK/T Cell LymphomaT-Cell Non-Hodgkin LymphomaT-cell Lymphoma (PTCL and CTCL)T-lymphoblastic Lymphoma

Phase 1

CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia
NCT04004637
PersonGen BioTherapeutics (Suzhou) Co., Ltd.Acute Lymphocytic Leukemia, NK/T Cell Lymphoma, T-lymphoblastic Lymphoma
Start: 2019-08-25End: 2021-06-01Target: 10Updated: 2020-09-28
CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas
RecruitingNCT06925464
Beijing GoBroad HospitalT-cell Lymphoma (PTCL and CTCL), T-Cell Non-Hodgkin Lymphoma
Start: 2025-04-01End: 2027-04-01Target: 36Updated: 2025-05-13

Unknown Phase

Multi-omics Profiling of Patients With Aplastic Anemia Before and After CD7-CAR-T Therapy
Active, not recruitingNCT07139600
Xuzhou Medical UniversityAplastic Anaemia, CAR-T, CD7 Positive
Start: 2024-08-01End: 2027-07-31Target: 5Updated: 2025-08-24

Related Papers

Engineering naturally occurring CD7− T cells for the immunotherapy of hematological malignancies
Blood2022-08-0163 citations
Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma
Clinical Cancer Research2022-04-18104 citations
A Single-Arm, Open-Label, Pilot Trial of Autologous CD7-CAR-T Cells for CD7 Positive Relapsed and Refractory T-Lymphoblastic Leukemia/Lymphoma
Blood2021-11-0519 citations
The Impact of the Immunophenotyping Characteristics of Patients' Peripheral Blood on the Manufacturing and Clinical Outcome of CD7-Targeted Chimeric Antigen Receptor T Cells
Blood2021-11-054 citations
A SINGLE‐ARM, OPEN‐LABEL, PILOT TRIAL OF AUTOLOGOUS CD7‐CAR‐T CELLS FOR CD7 POSITIVE RELAPSED AND REFRACTORY T‐LYMPHOBLASTIC LEUKEMIA/LYMPHOMA
Hematological Oncology2021-06-012 citations
First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.
Journal of Clinical Oncology2020-05-2019 citations